Media opportunity: the Canadian Cardiovascular Congress – Oct. 21 to 24, Vancouver

Media opportunity: the Canadian Cardiovascular Congress – Oct. 21 to 24, Vancouver

Canada NewsWire

News Canadians can use! The latest in research innovations. Solving complex challenges in heart disease.

VANCOUVER, Oct. 19, 2017 /CNW/ –

Logo: Canadian Cardiovascular Society (CNW Group/Heart and Stroke Foundation)

WHAT: Cardiology experts from Canada and around the world converge in Vancouver to brainstorm strategies to eradicate the impact of heart disease, showcase the latest research breakthroughs − and hear hundreds of speakers highlight innovations in science, prevention, treatment, and recovery. Congress delegates return home to their labs and practices armed with new tools and knowledge that will help prevent heart disease and save lives.

WHY: Heart disease is a leading cause of hospitalization and the second leading cause of death in Canada. Every seven minutes in Canada, someone dies from heart disease or stroke. Over 1.3 million survivors − and their families and caregivers − are living with the devastating after effects of heart disease. Millions of Canadians are at risk.

WHERE:Vancouver Convention Centre in Vancouver, BC

WHEN: Interviews available now through Oct 24, including onsite in Vancouver from Oct. 21 to 24


  • Leading heart experts: Available to talk about the impact of heart disease, why it matters to all Canadians, and give highlights of the research discoveries and innovations being presented at the 2017 Congress.
  • Congress researchers and presenters: The presenters featured below are available to talk about their presentations and impactful work in the area of heart health.
  • Heart disease survivors: Available to share their stories about living with heart disease.
  • Vancouver media: Heart experts will be available in Vancouver for on-site or in-studio interviews from October 21 to 24.


How to end a pandemic – Taking lessons from the fight against HIV/AIDS to heart.
This year’s Canadian Cardiovascular Congress opens on Saturday with a much-anticipated keynote lecture from Vancouver’s own Dr. Julio Montaner, who revolutionized antiretroviral therapy for HIV in the mid-90s, and a decade later pioneered the “Treatment as Prevention®” (TasP®) strategy to end the HIV/AIDS pandemic globally. TasP® calls for widespread HIV testing, immediate access to antiretroviral therapy and reducing the virus to undetectable levels to prevent progression to AIDS, AIDS-related mortality and transmission of HIV. With its proven success in British Columbia and around the world, TasP® is the backbone for the UNAIDS 90-90-90 Target − formally embraced by all UN signatory countries as the road map for the global control of HIV/AIDS by 2030.

Dr. Montaner further proposes using a Targeted Disease Elimination (TDE) approach to fight other contagious diseases, including infectious diseases (such as hepatitis C), as well as what he classifies as socially contagious diseases (such as Type 2 diabetes and  atherosclerosis), using the Treatment as Prevention (TasP®) model. He will challenge CCC delegates  to consider the potential impact Targeted Disease Elimination and TasP® would have on individual health outcomes, public health outcomes, and healthcare sustainability. (Julio Montaner, Vancouver, BC)

Hands on hearts
What does a diseased heart look like? Media are invited to join CCC delegates in an opportunity to view and handle actual human hearts, showing the effects of conditions such as cardiomyopathy, atherosclerotic coronary artery disease, prior valve replacement, complex congenital heart disease (including surgically corrected cases), and transplantation. Subspecialty cardiovascular pathologists will be on hand to explain the diseases and their impact on the heart. In the CCC Community Forum, Saturday to Monday, from 10 a.m. (Michael Seidman, Vancouver)

The e-cigarette debate: Which side of the light are you on?
Tobacco smoke kills over 37,000 people in Canada each year. Currently 5.2 million Canadians smoke; that’s 16.9% of Canadians aged 12 and over. Some smokers are now using e-cigarettes to satisfy their cravings and addiction. While e-cigarettes are likely less harmful than combustible tobacco, they are not without risks/harm. Some point to the potential of the devices to increase tobacco smoking by expanding the nicotine market among younger people, and renormalizing smoking; serving as a gateway for nicotine addiction and tobacco use. Currently, nicotine sold for use in e-cigarettes is banned in Canada but can be readily available under-the-counter, and there is legislation underway which would make e-cigarettes with nicotine legal for adult use. E-cigarettes are also only beginning to undergo rigorous clinical testing, so there is conflicting evidence comparing their potential as cessation devices to that of current pharmacotherapies and behavioral treatment interventions. Which side of the light should Canada be on? Part of the CCC debate series. (Pro: Simon Bacon, Montreal. Con: Andrew Pipe, Ottawa)

Protecting cancer patients’ hearts from cardiotoxic treatments
More cancer patients are surviving and living longer. Some lifesaving cancer therapies, however, can damage patients’ hearts and lead to other serious health concerns. How can healthcare providers work together to best protect the heart health of their cancer patients who undergo potentially cardiotoxic therapies? Experts from three Canadian programs in the emerging field of cardio-oncology share strategies in coordinating the prevention, diagnosis, and treatment of cardiac complications related to cancer therapy. (Christopher Johnson, Ottawa; Margot Davis, Vancouver; Christine Simmons, Vancouver)

Women in medicine: Breaking the glass ceiling by leaning in
Women have a long history in medicine, and there’s more progress ahead! In this inaugural CCC women’s session, cardiology and cardiac surgery mentors share stories with trainees about the experiences of women in medicine, and how they are “breaking the glass ceiling by leaning in.” The trainees, who come from a number of disciplines, will also launch their #LookLikeA… campaign to highlight the accomplishments of inspirational Canadian female role models in cardiovascular medicine. (Heather Ross, Toronto; Jacqueline Saw, Vancouver; Michelle Graham, Edmonton. Trainees: Varinder Randhawa, Toronto; Erin Rayner-Hartley, Vancouver; Laura Banks, Toronto; Katie Allan, Hamilton)

Celebrating outstanding achievements: Nominated by peers, the 2017 Canadian Cardiovascular Society Awards recognize exceptional contributions to the field of cardiology. This year’s recipients include:

  • Canadian Heart Failure Society 2017 Annual Achievement Award: Confronting a growing epidemic. Heart failure is a growing – and all too silent – epidemic in Canada. It is a significant health issue for hundreds of thousands of Canadians and their families, and its reach is expanding. When Dr. Peter Liu, chief scientific officer and vice president, research at the University of Ottawa Heart Institute, started in the field over 25 years ago, a diagnosis of heart failure was like a death sentence. Now, “these patients are living longer, true testaments to the scientific advances we have made together.” He’s played a significant role in that progress thanks to the support through organizations such as the Canadian Cardiovascular Society and Heart & Stroke. His lab has identified novel biomarker candidates for heart failure, and is evaluating them in new clinical settings to achieve personalized care. A passionate advocate for heart failure care and research, he is also been a key contributor to guidelines to guide health professionals in diagnosing and managing patients with heart failure. “We have traveled far, but there is still so much more journey to cover.” (Peter Liu, Ottawa)
  • Canadian Cardiovascular Society 2017 Research Achievement Award: Multiplying impact. How do you multiply an impact? Recognized for research in device and interventional therapy of cardiac arrhythmia associated with heart failure, Dr. Anthony Tang has a dual perspective as a clinician-scientist. “In clinical practice we serve one individual and offer help and assistance to the person,” says Dr. Tang, scientific director and CEO of the Cardiac Arrhythmia Network of Canada (CANet). “In research, we serve and offer advancement of medicine that affects many more individuals all over the world.” Among his major research contributions is the treatment-changing RAFT trial, which reduced rates of death and hospitalization for heart failure among patients with mild-to-moderate heart failure. One of his hopes is to see patient-centred and individualized arrhythmia care for all Canadians. (Anthony Tang, London, ON)

QUOTES: The Canadian Cardiovascular Congress
“The 2017 Canadian Cardiovascular Congress in Vancouver will be jam-packed with expert speakers, thought-provoking sessions, and opportunities to build connections. More than 2,500 health professionals in attendance will seize the opportunity to explore different perspectives, innovate and co-create, and present and discuss the latest science and new cardiovascular advances.”
Dr. Michelle Graham, scientific chair, Canadian Cardiovascular Congress

“The threat of heart disease is urgent and remains a stubborn leading cause of death and hospitalization. The learnings and connections made at the Congress will build capacity for an even stronger heart health community in Canada, shaping the future of diagnosis, treatment, and care management, which will save life’s precious moments and bring hope to families affected by heart diseases.”
Dr. Cindy Yip, director of heart health, Heart & Stroke


  • Heart disease is the second leading cause of death in Canada
  • An estimated 1.3 million Canadians are living with heart disease
  • There are an estimated 70,000 heart attacks in Canada; one every seven minutes
  • Up to 40,000 cardiac arrests occur each year in Canada; one every 13 minutes
  • Nine in 10 Canadians have at least one risk factor for heart disease and stroke; more than 24 million Canadians


Canadian Cardiovascular Congress

brings together more than 2,500 heart health experts to exchange ideas and present the latest breaking research. It is being held in Vancouver from October 21 to 24. #CCCVAN

Statements and conclusions of study authors are solely those of the study authors and do not necessarily reflect Foundation or CCS policy or position. Heart & Stroke and the Canadian Cardiovascular Society make no representation or warranty as to their accuracy or reliability.

Canadian Cardiovascular Congress
Co-hosted by the Canadian Cardiovascular Society and Heart & Stroke, CCC provides a broad spectrum of cardiovascular health professionals with current scientific information, accredited education opportunities and an ideal forum to connect with other cardiovascular health and care colleagues. This annual conference unites Canada’s cardiovascular community to network, learn and showcase the latest in research and innovations.

Canadian Cardiovascular Society 
The national voice for cardiovascular physicians and scientists. Its mission is to promote cardiovascular health and care through knowledge translation, professional development, and leadership in health policy.

Heart & Stroke
Life. We don’t want you to miss it. That’s why Heart & Stroke leads the fight against heart disease and stroke. We must generate the next medical breakthroughs, so Canadians don’t miss out on precious moments. Together, we are working to prevent disease, save lives and promote recovery through research, health promotion, and public policy.


SOURCE Heart and Stroke Foundation

View original content with multimedia:

FutureLand Corp. (FUTL) Closes Joint Venture with GreenLeaf Holdings, LLC. for Purchase of 80% of PLHS Life, LLC.

Denver, CO, Oct. 18, 2017 (GLOBE NEWSWIRE) — FutureLand Corp. (OTCPinks: FUTL), a leading provider of strategic real estate investment, grow facilities and material solutions to the medical and recreational global cannabis industry, announced today that it has closed a joint venture agreement to acquire PLHS Life, LLC, a Cannabis and Herbal supplement Retail Brand with multiple SKU’s, along with Greenleaf Holdings, LLC.   GreenLeaf Holdings and FutureLand acquired 80% of PLHS Life, LLC which closed on Oct. 11th, 2017.

Cameron Cox, CEO of FutureLand Corp. said, “This Company is very cool and very hip.  The product line is varied and enticing.  Michelle Kelley, of PL + HS, is an entrepreneur, singer and marketing guru.  She also has some very exciting new product ideas that are going to resonate extremely well with the culture!”

The Hemp/Cannabis industry has a multifaceted interchange of motivating factors that drive it forward.  Certainly, medical benefits top the list, but there are many more.  Mood facilitation, calming effects, general health and wellness along with recreational deployment open up many new products that will find a willing home here in the United States.  This is where Michelle Kelley’s “Peace, Love N Hippie Stuff” retail line will begin to take root.  CBD is a major factor in this plan.

According to an article written by Herb last month, “The U.S. marijuana industry is skyrocketing right now, with cannabis sales in America estimated to have reached $6.7 billion last year. But another, separate cannabis market will hit the $1 billion mark by 2020 – the fast-growing CBD market.  Hemp plants, a low-THC version of the same cannabis sativa plant from which the high THC varieties also spring, are the source of most cannabidiol (CBD) on the market. And the U.S. Ninth Circuit Court of Appeals has ruled that the Drug Enforcement Administration (DEA) can’t go after companies supplying hemp-based products without THC.  There are, of course, a myriad of uses for hemp, but CBD has outstripped the rest of them market-wise.  Brightfield Group, a market research firm, estimates that the CBD market totaled $170 million in 2016, and could top $1 billion within the next three years.”

PL+HS is a manufacturer and distributor of herbal supplements, everything from Kratom to Cannabis. They supply the world with the best herbal formulas anywhere using some of the best products on Earth.  One such product is MollyJane, an herbal mood enhancer.  They also have a full line of CBD infused cosmetic products, energy shots, creamers and coconut oil.  CannaKoKo, Herbalogix, CannaKoffee are but few of their brands.  Distribution deals are being structured that will allow PLHSLife to expand very rapidly.

Michelle Kelley, the face of PHLSLife, is a poet, musician and visionary for the cannabis movement.  She currently makes her home between Portland, Oregon and Los Angeles, CA. 

“We think that what Michelle is doing with PL+HS is really exciting and it’s a great privilege to work with Michelle on these very cutting-edge opportunities” said Maury Winnick a co-founder of Greenleaf Holdings, LLC.

About FutureLand Corp.

FutureLand Corp., a Colorado company, is a cannabis and hemp specialty zoned land leasing company formed to capitalize upon the emerging global cannabis market. FutureLand, focuses on target acquisition, zoning, license fulfillment, site plan preparation and financing of cannabis or hemp grow facilities throughout the United States. We give growers the opportunity to grow. We monetize through leasing the land, leasing the structures on the land, financing interest revenue and management fees associated with cultivation centers. FutureLand retains ownership of all the land and the structures. FutureLand leases to both medical marijuana, retail marijuana as well as industrial hemp growers. FutureLand does not currently grow, distribute or sell marijuana. To request further information about FutureLand, please email us at, log onto our website at, or visit us on FB @ futurelandcorp and Twitter @futurelandcorp.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This press release may contain forward-looking statements covered within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words “plan,” “expect,” “believe,” and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.


Media Contact

FutureLand Corp.

Home (720) 370-3554 Twitter - @futurelandcorp Facebook - futurelandcorp

Primary Logo

New report shows that tobacco use cost Canadians $16.2 billion in 2012

New report shows that tobacco use cost Canadians $16.2 billion in 2012

Canada NewsWire

Report also finds that three quarters of deaths as a result of tobacco use between 2002 and 2012 occurred in people aged 65 or older

OTTAWA, Oct. 16, 2017 /CNW/ – Tobacco is the leading preventable cause of disease and premature death in Canada. Despite declines in tobacco use over the past several decades, there are still millions of Canadians who use tobacco. The Government of Canada is taking action to reduce tobacco use in Canada.

A new report released today by the Conference Board of Canada, and funded by Health Canada, offers more evidence that tobacco use is a significant burden on all Canadians, costing society $16.2 billion in 2012, or $466 for every Canadian. This includes costs associated with direct health care, fire, policing, research and prevention as well as lost productivity due to disability and premature death. Most importantly, behind this dollar figure are more than 45,000 deaths in 2012, which represents 18% of all deaths in Canada that year. This means 125 Canadians died because of tobacco use every day in 2012.

The information provided in The Costs of Tobacco Use in Canada, 2012 report provides further evidence that more action is needed to reduce tobacco use in Canada. To that end, the Government of Canada introduced Bill S-5, the proposed Tobacco and Vaping Products Act and is modernizing the current Federal Tobacco Control Strategy. Bill S-5 balances the need to protect youth and non-users from the harms of vaping product use, including nicotine addiction, while allowing adults, particularly adult smokers, to legally access vaping products as a less harmful alternative to tobacco. In addition to its commitments relating to vaping and plain packaging, the Government of Canada has taken action to ban the use of menthol flavouring in cigarettes, blunt wraps, and most cigars.

The Government of Canada’s commitment to charting a new course in tobacco control is a component of the Vision for a Healthy Canada, which focuses on healthy eating, healthy living and a healthy mind. Some initiatives supporting this Vision include revisions to Canada’s food guide, a ban on partially hydrogenated oils (the main source of industrially produced trans fats in Canadian food), and immunizations and vaccine awareness initiatives, among others.

Quick facts:

  • Despite a steady decline in the number of smokers in Canada, the number of deaths due to tobacco use increased 22%, from 37,209 in 2002 to 45,464 in 2012.
    • 58.5% of these were men and 41.5% were women.
    • Three quarters of these deaths occurred in people aged 65 or older.
    • These premature deaths mean nearly 600,000 potential years of life lost.
    • Smoking rates were higher 30 to 50 years ago, so we can expect the numbers of deaths due to tobacco use to increase as our population ages.
  • Direct health costs also increased over this period, from $4.4 billion to $6.5 billion.
    • This included prescription drugs ($1.7 billion), physician care ($1.0 billion) and hospital care ($3.8 billion).
    • Federal, provincial and territorial governments spent $122 million on tobacco control and associated law enforcement activities.
  • Production losses were $9.5 billion, of which almost $2.5 billion were associated with premature deaths and $7.0 billion were associated with short- and long-term disability.
  • In the coming months Health Canada will:


“The costs of tobacco use in Canada are significant, and will continue to rise if we do not take new measures and sustain our collective commitment to tackle this issue. Aggressive action is needed, which is why we are moving forward with Bill S-5 and modernizing the current Federal Tobacco Control Strategy. I look forward to continuing our work with the provinces, territories, Indigenous communities and all Canadians to achieve this goal.”

The Honourable Ginette Petitpas Taylor

Minister of Health  

“Cigarette smoking is still the leading cause of premature death in Canada, killing half of all long-term users. Tobacco control is a public health priority that requires focused efforts to prevent youth from starting to smoke and to help current smokers quit.”

Dr. Theresa Tam

Chief Public Health Officer

Related Products

The Costs of Tobacco Use in Canada, 2012

Associated Links

Vision for a Healthy Canada 
An Overview of Canada’s Federal Tobacco Control Strategy 2012-17 
Share how tobacco products have affected your health 
Smoking and Tobacco 
Backgrounder on Plain Packaging 
Backgrounder on Vaping Products


SOURCE Health Canada

View original content: